Stockreport

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) [Yahoo! Finance]

Cadrenal Therapeutics, Inc.  (CVKD) 
PDF It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds. Orphan Drug and Fast Track [Read more]